Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTANIL vs DAYPRO ALTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Rheumatoid arthritis,Osteoarthritis,Juvenile idiopathic arthritis,Ankylosing spondylitis (off-label),Acute gout (off-label)
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily hepatic via cytochrome P450 (CYP) 2C9 and CYP2C8; minor metabolism via glucuronidation. Metabolites are inactive.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
>99.5% bound to albumin.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
0.15-0.25 L/kg; low Vd indicates extensive plasma protein binding and limited tissue distribution.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
Oral: approximately 100% (well absorbed with no significant first-pass metabolism).
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
For patients with creatinine clearance (Cr Cl) of 50-79 m L/min: no dose adjustment is generally required, but monitor for adverse effects. For Cr Cl 30-49 m L/min: reduce dose by 50% or use 600 mg once daily. For Cr Cl <30 m L/min: use is contraindicated. End-stage renal disease (ESRD): avoid use.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Child-Pugh Class A (mild impairment): no dose adjustment needed. Child-Pugh Class B (moderate impairment): reduce dose by 50% or use 600 mg once daily; monitor closely. Child-Pugh Class C (severe impairment): use is contraindicated. No specific studies; caution advised.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Not approved for pediatric use. Safety and efficacy have not been established in patients under 18 years. Avoid use in children and adolescents unless under expert guidance and with caution.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Elderly patients (≥65 years) are at increased risk for NSAID-related adverse effects, including GI bleeding, renal impairment, and cardiovascular events. Initiate therapy at the lowest effective dose (e.g., 600 mg once daily) and monitor renal function, blood pressure, and for signs of GI toxicity. Avoid use if possible in patients with high cardiovascular risk or history of GI ulceration.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Cardiovascular risk: NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Gastrointestinal risk: NSAIDs increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time without warning.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Cardiovascular thrombotic events (MI, stroke),Gastrointestinal bleeding, ulceration, perforation,Renal toxicity (elevated creatinine, nephrotoxicity),Hepatic effects (transaminase elevations, rare severe hepatotoxicity),Hypertension exacerbation,Fluid retention and edema,Anaphylactoid reactions,Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome),Premature closure of ductus arteriosus in pregnancy,Hematologic effects (anemia, bleeding)
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Hypersensitivity to oxaprozin or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In setting of coronary artery bypass graft (CABG) surgery,Advanced renal disease,Pregnancy (third trimester) due to risk of preterm closure of ductus arteriosus and oligohydramnios
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
May be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of GI bleeding. No specific food restrictions otherwise.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimester: Avoid after 30 weeks due to premature closure of ductus arteriosus and oligohydramnios. DAYPRO ALTA (oxaprozin) is contraindicated in third trimester.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Oxaprozin is excreted in human milk; M/P ratio is approximately 0.5. Due to potential adverse effects on infant, caution is advised. Use only if benefit outweighs risk, consider alternative agents.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
In pregnancy, oxaprozin clearance may increase; however, no specific dose adjustment is recommended. Use lowest effective dose for shortest duration during first and second trimesters. Avoid in third trimester.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Daypro Alta (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~40-50 hours) allowing once-daily dosing. Monitor for GI bleeding, renal impairment, and cardiovascular events. Use with caution in elderly and those with renal insufficiency. Avoid in patients with aspirin-sensitive asthma or NSAID allergy.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
Take with food or milk to reduce stomach upset.,Do not take other NSAIDs or aspirin while on this medication.,Report any signs of stomach bleeding (black stools, coffee-ground vomit), chest pain, or swelling.,Avoid alcohol as it increases GI bleeding risk.,Tell your doctor about all medications, especially blood thinners and diuretics.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTANIL vs DAYPRO ALTA, answered by our medical review team.
ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. DAYPRO ALTA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTANIL and DAYPRO ALTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. The standard adult dose of DAYPRO ALTA is: Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTANIL and DAYPRO ALTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. DAYPRO ALTA is classified as Category C. First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.